Table 1:
Expression of Long term non-progressor (LTNP) microRNAs and Viramic progressors microRNAs
| microRNA | EC/VC/VP | Expression | Method | Matrial (Plasma, PBMC, T cell) | Sample (n) | Note | Ref |
|---|---|---|---|---|---|---|---|
| miR-16 | EC and untreated viremic patients | Up | TaqMan low-density arrays (TLDA), qPCR | PBMC | 13 (EC+VC) | (78) | |
| miR-22 | EC and untreated viremic patients | Up | TLDA | PBMC | 13 (EC+VC) | (78) | |
| miR-155 | EC and untreated viremic patients | Up | qPCR | PBMC | 13 (EC+VC) | (78) | |
| miR-34a | Untreated viremic patients | Up | qPCR | PBMC | 6 | Significantly correlated with CD4 counts only in elite controllers | (78) |
| miR-21 | Untreated viremic patients | Up | qPCR | PBMC | 6 | (78) | |
| miR-27a | Untreated viremic patients | Up | qPCR | PBMC | 6 | (78) | |
| miR-181b | Untreated viremic patients | Up | Nanostring, qPCR | PBMC | 6 | Negatively correlated with CD4 counts | (78) |
| miR-181d | Untreated viremicpatients | Up | Nanostring | PBMC | 6 | (78) | |
| miR-155 | Untreated viremic patients | Up | Nanostring | PBMC | 6 | (78) | |
| miR-9 | Untreated viremic patients | Up | Nanostring | PBMC | 6 | (78) | |
| miR-29b-3p | EC | Up | Real-time qPCR | Plasma | 18 (9 EC+9 CH) | The expression level of miR-29b-3p was higher in plasma from ECs than chronic HIV progressors (CH). | (69) |
| miR-33a-5p | EC | Up | Real-time qPCR | Plasma | 18 (9 EC+9 CH) | The expression level of miR-33a-5p was higher in plasma from ECs than CHs | (69) |
| miR-146a-5p | EC | Up | Real-time qPCR | Plasma | 18 (9 EC+9 CH) | The expression level of miR-146a-5p was higher in plasma from ECs than CHs. | (69) |
| miR-221 | EC | Up | TLDA | PBMC | 8 | Upregulated in Ec and uninfected individuals while downregulated in VCs and patients under ART | (77) |
| miR-27b | EC | Up | TLDA | PBMC | 8 | Upregulated in Ec and uninfected individuals while downregulated in VCs and patients under ART | (77) |
| miR-29b | EC | Up | TLDA | PBMC | 8 | Upregulated in Ec and uninfected individuals while downregulated in VCs and patients under ART | (77) |
| miR106a | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| mir-155 | EC and VC | Up | Microarray | CD8+T- cells | 30 (EC+VC) | Upregulated mir-155 expression when resting CD8+ T-cells were stimulated | (66) |
| miR-140 | VP | Up | TLDA | CD8+ T-cells | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-146a | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-4484 | EC, VC and VP | Up | Microarray | CD8+T- cells | 43 (EC+VC+VP) | Upregulated mir-4484 expression when resting CD8+ T-cells were stimulated | (66) |
| miR-125a | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-484 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-590 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-17 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-146b | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-155 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-16 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-186 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-27a | EC | Up | TLDA | PBMC | 8 | Upregulated in Ec and uninfected individuals while downregulated in Vcs and patients under ART | (77) |
| miR-191 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-197 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-339 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-374 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-200b | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-200c | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-422 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-454 | VP | Up | TLDA | PBMC | 8 | Upregulated in VCs and patients under ART while Downregulated in ECs and uninfected individuals | (77) |
| miR-125b | Untreated viremic patients | Down | TLDA | PBMC | 6 | (78) | |
| Let-7g | Untreated viremic patients | Down | Nanostring, TLDA | PBMC | 6 | (78) | |
| miR-146b-5p | Untreated viremic patients | Down | Nanostring, TLDA | PBMC | 6 | (78) | |
| miR-150 | Untreated viremic patients | Down | Nanostring | PBMC | 6 | Considerably positively correlated with CD4 counts | (78) |
| miR-150 | EC and untreated viremic patients | Down | qPCR | PBMC | 13 (EC+VC) | Considerably positively correlated with CD4 counts | (78) |
| miR-29a | Untreated viremic patients | Down | Nanostring, TLDA, qPCR | PBMC | 6 | Considerably positively correlated with CD4 counts | (78) |
| miR-29b | Untreated viremic patients | Down | Nanostring | PBMC | 6 | (78) | |
| miR-29c | Untreated viremic patients | Down | Nanostring | PBMC | 6 | (78) | |
| miR-221 | VP | Down | TLDA | PBMC | 8 | Downregulated in VCs and patients under ART while upregulated in ECs and uninfected individuals | (77) |
| miR-27a | VP | Down | TLDA | PBMC | 8 | Downregulated in VCs and patients under ART while upregulated in ECs and uninfected individuals | (77) |
| miR-27b | VP | Down | TLDA | PBMC | 8 | Downregulated in VCs and patients under ART while upregulated in ECs and uninfected individuals | (77) |
| miR-29b | VP | Down | TLDA | PBMC | 8 | Downregulated in VCs and patients under ART while upregulated in ECs and uninfected individuals | (77) |
| miR106a | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-125a | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-140 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-146a | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-146b | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-155 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-16 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-17 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-186 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-191 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-197 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-200b | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-200c | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-339 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-374 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-422 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-454 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-484 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-590 | EC | Down | TLDA | PBMC | 8 | Downregulated in ECs and uninfected individuals while Upregulated in VCs and patients under ART | (77) |
| miR-4734 | VP | Down | Microarray | CD8+ T-cells | 13 | Downregulated miR-4734 in VPs Compared with uninfected individuals | (66) |
| miR-4505 | EC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-4505 in ECs Compared with uninfected individuals | (66) |
| miR-4505 | VC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-4505 in VCs Compared with uninfected individuals | (66) |
| mir-4508 | EC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-4508 in ECs Compared with VP | (66) |
| miR-3620 | EC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-3620 in ECs Compared with VP | (66) |
| miR-4492 | EC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-4492 in ECs Compared with VP | (66) |
| miR-4507 | EC | Down | Microarray | CD8+ T-cells | 15 | Downregulated miR-4507 in ECs Compared with VP | (66) |
| miR-181a | VP | Down | Microarray | CD8+ T-cells | 13 | Downregulatedmir-181a expression when resting CD8+ T-cells were stimulated | (66) |
| let-7b-5p | VP | Down | Microarray | CD8+ T-cells | 13 | Downregulated let-7b-5p expression when resting CD8+ T-cells were stimulated | (66) |
| miR-150 | VC | Down | Microarray | CD8+ T-cells | 15 | Downregulated mir-150 expression when resting CD8+ T-cells were stimulated | (66) |
| miR-1202 | VC | Down | Microarray | CD8+ T-cells | 15 | Downregulated mir-1202 expression when resting CD8+ T-cells were stimulated | (66) |